Literature DB >> 2108953

Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes.

Y Sumita1, M Fukasawa, T Okuda.   

Abstract

We investigated the binding affinities of SM-7338 for penicillin-binding proteins (PBPs) and the morphological changes induced by it compared with those of imipenem. Both SM-7338 and imipenem had the highest binding affinities for PBP-2 of Escherichia coli, which were in good agreement with the primary morphological response of spherical cell formation. SM-7338 also showed high affinities for PBP-1A, -1Bs, and -3, and imipenem showed high affinities for PBP-1A and -1Bs but not for PBP-3. At 4-fold MIC, SM-7338 induced a indeterminate form, whereas imipenem did not. This may be due to the higher affinity of SM-7338 for PBP-3 compared to that of imipenem. Against Pseudomonas aeruginosa, SM-7338 had very high affinities for PBP-2 and -3, and imipenem had higher affinities for PBP-2 and -1A. SM-7338 induced this organism to filamentous cells at a concentration lower than its MIC, bulge cells at 2-fold MIC, and spherical cells at 4-fold MIC, while imipenem principally induced round cell formation at each concentration. These morphological differences in P. aeruginosa may be due to the differences in binding profiles to PBPs. We also studied the affinities for PBPs using radioactive SM-7338. The data obtained supported these results.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108953     DOI: 10.7164/antibiotics.43.314

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  19 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  In vitro antibacterial activity of KP-736, a new cephem antibiotic.

Authors:  T Maejima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.

Authors:  Yutaka Ueda; Katsunori Kanazawa; Ken Eguchi; Koji Takemoto; Yoshiro Eriguchi; Makoto Sunagawa
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 4.  Morphological and ultrastructural changes in bacterial cells as an indicator of antibacterial mechanism of action.

Authors:  T P Tim Cushnie; Noëlle H O'Driscoll; Andrew J Lamb
Journal:  Cell Mol Life Sci       Date:  2016-07-08       Impact factor: 9.261

5.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

Review 6.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

7.  Transient carbapenem resistance induced by salicylate in Pseudomonas aeruginosa associated with suppression of outer membrane protein D2 synthesis.

Authors:  Y Sumita; M Fukasawa
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Pharmacodynamic effects of meropenem on gram-negative bacteria.

Authors:  H Hanberger; E Svensson; L E Nilsson; M Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

10.  Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins.

Authors:  A Raimondi; A Traverso; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.